INTEGRATING IMMUNO-ONCOLOGY AGENTS INTO CANCER TREATMENT PROTOCOLS
Main Article Content
Keywords
Immuno-Oncology, Cancer Treatment, Immune Checkpoint Inhibitors, Therapeutic Efficacy, Treatment Sequencing,
Abstract
This review paper explores the incorporation of immuno-oncology drugs into cancer therapy protocols, which is a significant breakthrough in oncological research. By utilizing the body's own immune defenses, these medicines have the remarkable ability to transform cancer treatment, improving the effectiveness of treatment and prolonging patient lives. To successfully navigate the complex field of immuno-oncology, one must possess a thorough comprehension of its various problems and potential advantages. This study consolidates crucial factors necessary for enhancing therapeutic benefits and limiting hazards ranging from optimizing treatment sequencing to managing immune-related adverse events.The review provides information on current progress in immuno-oncology research, including new approaches to address resistance to therapies and improve treatment effectiveness. This review offers a thorough and detailed summary of the recent advancements in immuno-oncology, effectively connecting scientific findings with their practical use in clinical settings. By combining several fields of study and fostering new ideas, immuno-oncology has the potential to fundamentally change the way cancer patients are treated. Through the promotion of individualized and efficient therapeutic treatments, immuno-oncology is positioned to boost clinical results and elevate the quality of life for patients engaged in the fight against cancer.
Downloads
References
1. Litan A, Langhans SA. Cancer as a channelopathy: ion channels and pumps in tumor development and progression. Front Cell Neurosci. (2015) 9:86. doi: 10.3389/fncel.2015.00086 2. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 16:275–87. doi: 10.1038/nrc.2016.36 3. Frampton GM, Fabrizio DA, Chalmers ZR, Sun JX, Miller VA, Stephens PJ. Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes. Ann Oncol. (2016) 27:15–42. doi: 10.1093/annonc/mdw363.01 4. Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. (2017) 14:717–34. doi: 10.1038/nrclinonc.2017.101 5. Tan P, He L, Han G, Zhou Y. Optogenetic immunomodulation: shedding light on antitumor immunity. Trends Biotechnol. (2017) 35:215–26. doi: 10.1016/j.tibtech.2016.09.002 6. Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov. (2017) 16:264–72. doi: 10.1038/nrd.2016.233 7. Webb S. The cancer bloodhounds. Nat Biotechnol. (2016) 34:1090–4. doi: 10.1038/nbt.3717 8. Tanase CP, Codrici E, Popescu ID, Mihai S, Enciu A-M, Necula LG, et al. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget (2017) 8:18497–512. doi: 10.18632/oncotarget.14501 9. Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The challenge for development of valuable immuno-oncology biomarkers. Clin Cancer Res (2017) 23:4970–9. doi: 10.1158/1078-0432.CCR-16-3063 10. Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. (2015) 16–42. doi: 10.1016/S1470-2045(14)70375-4 11. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. (2014) 371:2189–99. doi: 10.1056/NEJMoa1406498 12. Vonderheide RH, Nathanson KL. The road to personalized cancer vaccines. Nat Med. (2013) 19:1098–100. doi: 10.1038/nm.3317y 13. Miller L. Mutational load is only one piece of the immunotherapy puzzle. Target Oncol. (2017). Available online at: Accessed March 22, 2017 14. Au Q, Nguyen K, Padmanabhan R, Kuller A, Moler E, Hoe N. Abstract 4146: MultiOmyx multiplexed tumor infiltrating lymphocyte panel provides comprehensive immunophenotyping from a single FFPE slide. Cancer Res. (2016) 76. doi: 10.1158/1538-7445.AM2016-4146 15. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. (2018) 24:144–53. doi: 10.1038/nm.4466 16. Zill O, Mortimer S, Banks K, Nagy R, Chudova D. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. In: 2016 ASCO Annual Meeting | Abstracts | Meeting Library. Chicago, IL: Journal of Clinical Oncology. doi: 10.1200/JCO.2016.34.18_suppl.LBA11501 (Accessed April 12, 2017) 17. Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res (2017 23:4959–69. doi: 10.1158/1078-0432.CCR-16-3065 18. Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci USA. (2016) 113 77. doi: 10.1073/pnas.1607836113 19. Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. (2015) 75:2139–45. doi: 10.1158/0008-5472.CAN-15-0255 20. Tunstall KL. Quantifying immune cell distribution in the tumor micro- environment using HALO TM spatial analysis tools. (2016) Available online at: Accessed July, 2016 21. Bomben V. C., Turner K. L., Barclay T. T., Sontheimer H. (2011). Transient receptor potential canonical channels are essential for chemotactic migration of human malignant gliomas. J. Cell Physiol. 226, 1879–1888. PMC 22. Brackenbury W. J., Davis T. H., Chen C., Slat E. A., Detrow M. J., Dickendesher T. L., et al. . (2008). Voltage-gated Na+ channel beta1 subunit-mediated neurite outgrowth requires Fyn kinase and contributes to postnatal CNS development in vivo. J. Neurosci. 28, 3246–3256. PMC 23. Brackenbury W. J. (2012). Voltage-gated sodium channels and metastatic disease. Channels (Austin) 6, 352–361. PMC 24. Catacuzzeno L., Aiello F., Fioretti B., Sforna L., Castigli E., Ruggieri P., et al. . (2011). Serum-activated K and Cl currents underlay U87-MG glioblastoma cell migration. J. Cell. Physiol. 226, 1926–1933. PMC 25. Brisson L., Driffort V., Benoist L., Poet M., Counillon L., Antelmi E., et al. . (2013). NaV1.5 Na+ channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia. J. Cell Sci. 126, 4835–4842. 26. Brown E. J. (2002). Integrin-associated proteins. Curr. Opin. Cell Biol. 14, 603–607. 27. Bustin S. A., Li S. R., Dorudi S. (2001). Expression of the Ca2+-activated chloride channel genes CLCA1 and CLCA2 is downregulated in human colorectal cancer. DNA Cell Biol. 20, 331–338. 28. Camerino D. C., Tricarico D., Desaphy J. F. (2007). Ion channel pharmacology. Neurotherapeutics 4, 184–198. 29. Cardone R. A., Casavola V., Reshkin S. J. (2005). The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat. Rev. Cancer 5, 786–795. 30. Catacuzzeno L., Fioretti B., Franciolini F. (2012). Expression and role of the intermediate-conductance calcium-activated Potassium channel KCa3.1 in Glioblastoma. J. Signal Transduct. 2012:421564. PMC
Article Sidebar
Article Details
Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.